Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health

Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166559. doi: 10.1016/j.bbadis.2022.166559. Epub 2022 Sep 26.

Abstract

Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.

Keywords: COVID; Cardiometabolic; Diabetes; Inflammation; Molecular.

Publication types

  • Review

MeSH terms

  • Adipokines
  • COVID-19*
  • Cardiovascular Diseases* / epidemiology
  • Cytokines
  • Diabetes Mellitus, Type 2* / complications
  • Humans
  • Interferon-gamma
  • Interleukin-10
  • Interleukin-2
  • Interleukin-4
  • Interleukin-6
  • Interleukin-8
  • Obesity / complications
  • Obesity / epidemiology
  • Pandemics
  • RNA, Viral
  • SARS-CoV-2

Substances

  • Adipokines
  • Cytokines
  • Interleukin-2
  • Interleukin-6
  • Interleukin-8
  • RNA, Viral
  • Interleukin-10
  • Interleukin-4
  • Interferon-gamma